Stockscreener 앱 받기
9.40
1.47%
-0.14
시간 외 거래:
9.40
Kura Oncology Inc 주식(KURA)의 최신 뉴스
KURA Reiterates by Citizens -- Price Target Maintained at $24.00 - GuruFocus
Citizens reiterates Kura Oncology stock rating on strong trial data - Investing.com
Citizens reiterates Kura Oncology stock rating on strong trial data By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Kura Oncology, Inc. (KURA) Presents at European Hematology Association (EHA) 2026 CongressSlideshow - Seeking Alpha
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
KURA: Ziftomenib plus 7+3 shows high response and survival rates in AML, supporting phase III trials - TradingView
KURA: Ziftomenib plus 7+3 shows high, durable remission and survival in AML, supporting phase III trials - TradingView
Kura Oncology Inc EHA Investor Event Transcript - GuruFocus
Number of shareholders of Kura Oncology, Inc. – NASDAQ:KURA - TradingView
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results For Ziftomenib And 7+3 Combination In Newly Diagnosed AML - marketscreener.com
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term - GlobeNewswire
Kura Oncology Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - marketscreener.com
Why Did KURA Stock Jump 13% In Pre-Market Today? - Stocktwits
The Technical Signals Behind (KURA) That Institutions Follow - Stock Traders Daily
How The Kura Oncology (KURA) Investment Narrative Is Evolving Without New Analyst Revisions - Yahoo Finance
Kura Oncology, Inc. (KURA) Discusses Clinical Data and Updated Development Strategy for DarlifarnibSlideshow - Seeking Alpha
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology Advances Targeted Combo in Tough Head and Neck Cancer - TipRanks
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Analysts’ Top Healthcare Picks: Kura Oncology (KURA), Align Tech (ALGN) - The Globe and Mail
UBS Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Director at Kura Oncology (NASDAQ: KURA) receives 35,000-share option grant - Stock Titan
Kura Oncology (KURA) director receives grant of 35,000 stock options at $8.77 - Stock Titan
Kura Oncology (KURA) awards director stock options at $8.77 strike - Stock Titan
Kura Oncology (KURA) director receives 35,000 options at $8.77 strike price - Stock Titan
Kura Oncology (KURA) director Carol Schafer granted 35,000 stock options - Stock Titan
Director Mary Szela awarded 35,000 Kura Oncology (KURA) options - Stock Titan
Kura Oncology (KURA) director receives option grant for 35,000 shares at $8.77 - Stock Titan
[8-K] Kura Oncology, Inc. Reports Material Event - Stock Titan
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - Moomoo
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald reiterates Kura Oncology stock Overweight rating - Investing.com
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Citizens reiterates Kura Oncology stock rating on FIT-001 data By Investing.com - Investing.com South Africa
Citizens reiterates Kura Oncology stock rating on FIT-001 data - Investing.com
Kura Oncology Inc ASCO Investor Event Transcript - GuruFocus
KURA Highlights Promising Data for Darlifarnib in KRAS-Mutant Ca - GuruFocus
Kura Oncology reports phase 1a data for cancer drug combination - Investing.com UK
Kura Oncology reports phase 1a data for cancer drug combination By Investing.com - Investing.com Australia
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy - The Manila Times
Kura Oncology Reports Promising Phase 1a Results for Darlifarnib in Multiple KRAS-Mutant Cancers and Announces New Platform Study - Quiver Quantitative
Kura Oncology Highlights Darlifarnib’s Potential as a - GlobeNewswire
Kura Oncology Stock Hits Day Low of $9.03 Amid Price Pressure - Markets Mojo
Kura Oncology, Kyowa Kirin report trial results for AML drug By Investing.com - Investing.com South Africa
Kura Oncology, Kyowa Kirin report trial results for AML drug - Investing.com
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML - The Manila Times
Blood journal reports 87% response with Kura AML drug combo - Stock Titan
KURA News | KURA ONCOLOGY INC (NASDAQ:KURA) - ChartMill
Kura Oncology Stock Hits Day Low of $10.39 Amid Price Pressure - Markets Mojo
Citizens reiterates Kura Oncology stock rating on FTI platform progress By Investing.com - Investing.com Australia
Citizens reiterates Kura Oncology stock rating on FTI platform progress - Investing.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pacific Edge Limited (OtherPFGTF), Kura Oncology (KURA) and Eli Lilly & Co (LLY) - The Globe and Mail
1.27%
1.43%
자본화:
|
볼륨(24시간):